Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?

Chakraborty, Dwaipayan Sarathi; Hazra, Avijit; Sil, Amrita; Pain, Shantasil

Chakraborty, Dwaipayan Sarathi; Hazra, Avijit; Sil, Amrita; Pain, Shantasil.

Afiliación

Chakraborty DS; Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.
Hazra A; Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.
Sil A; Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.
Pain S; Department of Medicine, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.

J Family Med Prim Care ; 8(10): 3173-3178, 2019 Oct.

Article en En | MEDLINE | ID: mdl-31742138

Palabras clave

Diarrhoea; irritable bowel syndrome; mebeverine; randomized controlled trial

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Aspecto: Patient_preference Idioma: En Revista: J Family Med Prim Care Año: 2019 Tipo del documento: Article País de afiliación: India Pais de publicación: India

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google